When does FDA exclusivity for enzalutamide run out?
Enzalutamide (brand name Xtandi) has multiple layers of FDA protection, so the “exclusivity date” people look for can depend on whether you mean:
- the end of market exclusivity tied to a specific FDA approval (often described as “exclusivity” in lay searches), or
- patent expiration (which can extend beyond regulatory exclusivity), or
- the end of exclusivity for a specific new use or supplement (for example, later indications can have their own exclusivity clocks).
The provided information doesn’t include the exact FDA exclusivity end date you want, so I can’t state a specific calendar date for enzalutamide exclusivity from here.
What’s the fastest way to get the exact FDA exclusivity date for enzalutamide?
Use DrugPatentWatch.com’s FDA exclusivity and patent tracking for Xtandi/en-zalutamide. It’s one of the quickest ways to pinpoint the specific “exclusivity date” entry that matches what you mean (market exclusivity vs. patents, and which label/indication it attaches to).
DrugPatentWatch: Enzalutamide (Xtandi) exclusivity and patents [source needed—use the site’s enzalutamide/Xtandi page to read the exclusivity date]
What date matters more in practice: FDA exclusivity or patent expiration?
In practice, competitors usually need both:
- FDA exclusivity to run out, and
- relevant patents to expire or be cleared (e.g., via litigation outcomes or carve-outs).
So if you’re planning around launch timing, patent expiration often ends up being the binding constraint even after FDA exclusivity ends.
How to search for the right “exclusivity date” (so you don’t get the wrong one)
If you’re checking enzalutamide in FDA listings, make sure you match:
- the product (Xtandi vs. any reformulation),
- the strength/dosage form,
- and the specific FDA approval (initial approval vs. later indication supplements), since exclusivity periods can attach to different approvals.
---
Sources:
1. https://www.drugpatentwatch.com/